A full and energising first day at the World Evidence, Pricing and Access Congress in Amsterdam.
It was a pleasure to reconnect with long-standing connections, meet new ones, and continue conversations across the access community.
We are pleased to be here with our colleagues from IGES Pharma as part of the athagoras Group, and to have the support of our group leadership, Giuseppe Pileggi and Yulia Barinskaya, on site.
Across sessions and discussions, three themes clearly stand out:
📍 The growing role of AI in evidence generation, pricing and access strategy
📍 Implementation realities of Joint Clinical Assessment JCA
📍 Ongoing uncertainty around the US Most Favored Nation MFN policy
The access landscape is evolving quickly, and the appetite for rigorous, decision ready RWE has never been stronger.
We ended the day with a team dinner and are looking forward to the final day tomorrow.
How are AI, JCA, or MFN shaping your access strategy this year?
